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Background: While people who inject drugs (PWID) typically use peripheral veins, some inject 
into their central veins, including the femoral and jugular veins. Injection into the jugular vein 
can have serious adverse health consequences, including jugular vein thrombosis, deep neck 
infections, pneumothorax, endocarditis and sepsis. This study examined the prevalence of, 
and factors associated with, jugular vein injection among a large sample of PWID in the United 
Kingdom. 
Method: Unlinked anonymous surveys (2011-14) recruited PWID from agencies providing 
services to this population. Self-reported demographic and injection-related data were 
collected from consenting respondents using a brief questionnaire and dried blood spot 
samples were tested for exposure to HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV). 
Univariate and multivariable logistic regression were used to examine factors associated with 
jugular vein injection. 
Results: Among 5,261 PWID, one third had injected into a central vein in the previous 28 days, 
including 6% (n=339) who had injected into their jugular vein and 1% (n=52) who had used 
this site exclusively for recent injections. Factors independently associated with recent jugular 
vein injection in multivariable analysis included female gender, a lifetime history of 
imprisonment, sharing needles and syringes, poly-drug injection and injection into multiple 
body sites. Jugular vein injection was also associated with experiencing injection-related 
injuries, although no associations were identified with respect to exposure to blood borne viral 
infections. 
Conclusion: A significant minority of PWID inject into the jugular vein in the United Kingdom. 
Public health responses should investigate ways to support and promote good injection site 
management in order to minimise vascular damage and reduce problems with peripheral 
venous access. Women who inject drugs, PWID with a history of imprisonment and those 
people who are experiencing early signs of injection-related skin and soft tissue injuries are 




People who inject drugs (PWID) typically inject into the peripheral veins in their arms (Harris & 
Rhodes, 2012). Problems with vascular access to peripheral veins may arise as a 
consequence of the vascular damage that can occur after regular injection into a body site 
over a long period of time. Damage to a peripheral vein, such as venous sclerosis (the 
hardening and thickening of the walls of a vein), can limit venous access at that site by making 
it difficult to locate the vein or inject into it. This limited venous access may result in people 
making several attempts to inject into a body site or using multiple sites on their body for 
injection (Darke, et al., 2001; Harris & Rhodes, 2012; Maliphant & Scott, 2005). It may also 
result in accidental subcutaneous and intramuscular injections, or ‘missed hits’, which can 
result in soft-tissue damage and infections (Hope, et al., 2016). Over time injection into 
accessible peripheral veins, such as the arms or legs, can become increasingly difficult (Darke, 
et al., 2001). An alternative is to inject into central veins, such as the femoral or jugular veins 
(Ciccarone & Harris, 2015). Injection into the central veins can be more difficult, and has high 
risk of complications and harm (Darke, et al., 2001). The use of such veins was often regarded 
as the “last resort” for people with vascular damage who had exhausted the option of using an 
alternate injection site (Darke, et al., 2001; Maliphant & Scott, 2005; Rhodes, 1995). However, 
studies indicate that the practice of injection into the central veins might have become more 
common in some countries, such as the UK, over time (Rhodes, et al., 2006; Hope, et al., 2015 
). Although a number of studies have examined injection into the femoral vein (‘groin injection’) 
and the factors associated with this practice (Maliphant & Scott, 2005; Rhodes, et al., 2006; 
Coffin, et al., 2012; Ti, et al., 2014; Hope, et al., 2015 ), there have been very few studies that 
have investigated injection into the jugular vein (‘neck injection’). 
 
The few studies that have investigated injection into the jugular vein have reported substantial 
differences in the prevalence of this practice. In a recent study in Tijuana (Mexico) one third of 
PWID reported that the neck was the main site used for injection in 2011 (Rafful, et al., 2015). 
The high prevalence of jugular vein injection in Tijuana may reflect  the predominance of black 
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tar heroin in this region, the use of this form of heroin has been associated with venous 
sclerosis that makes intravenous injection difficult (Ciccarone, 2009 ; Rafful, et al., 2015). In a 
cohort study in Vancouver (Canada), around one quarter of participants who were followed-up 
during 2004-2005 had used the jugular vein as an injection site during the preceding 6 months 
(Hoda, et al., 2008). In this Canadian study, injection into the jugular vein was associated with 
daily injection and the authors hypothesized that venous access difficulties were likely to occur 
among people engaging in high frequency injecting drug use (Hoda, et al., 2008). Frequent 
injection (that is injecting more than once daily) was also associated with jugular vein injection 
in Tijuana (Rafful, et al., 2015), and in both the Canadian and Mexican studies people who had 
injected into their jugular vein were more likely to require or seek assistance with injecting 
(Hoda, et al., 2008; Rafful, et al., 2015). In a national study undertaken in Iran in 2007, 12% of 
people who injected heroin daily or more frequently reported their neck as their usual injection 
site (Karimi, et al., 2014). However, an older study undertaken in Sydney (Australia) in 1999, 
found jugular vein injection to be much less common, with 10% of PWID reporting that they 
had ever injected into their neck and 4% reporting that they had done so in the previous six 
months (Darke, et al., 2001).  
 
These studies support the notion that the practice of injection into the jugular vein may be 
relatively common. This is a concern as injection into the jugular vein has been associated with 
a number of significant, and potentially costly, health problems (Lewis, et al., 1980; Myers, et 
al., 1988; Hoda, et al., 2008; Rafful, et al., 2015), including jugular vein thrombosis, deep neck 
infections, pneumothorax, endocarditis and sepsis (Lewis, et al., 1980; Myers, et al., 1988). 
This study used data from a large national cross-sectional survey of PWID in the United 
Kingdom (UK), which purposively collected information on the injection sites used during the 
previous 28 days. Using this data we investigate a) the extent of jugular vein injection in the 
UK, b) factors associated with jugular vein injection, and c) health-related harms associated 





Recruitment and data  
PWID at sentinel locations have been recruited into a voluntary unlinked-anonymous 
monitoring (UAM) system in the UK since 1990.  Methodological details of this system, a series 
of annual cross-sectional surveys, have been published previously (Hope, et al., 2014). Briefly, 
agencies providing services to PWID (e.g. needle and syringe programmes and providers of 
addiction services such as opiate substitution therapy) invite clients who have ever injected 
psychoactive drugs to participate in the survey each year. The agencies are sentinel locations 
throughout the UK, except Scotland, and are selected to reflect both the geographic distribution 
and range of services offered to PWID. People who consent to participate provide a fingerstick 
capillary dried blood spot (DBS) and self-complete a short questionnaire focused on the 
injection of psychoactive drugs. The survey instrument includes a multi-response question on 
the use of specific injection sites, participants who had injected during the preceding 28 days 
were asked: “In the last 28 days, into which parts of your body did you inject drugs?” and 
indicate all of the listed body sites that they had used. In 2011, as part of questionnaire review 
and stakeholder feedback, the response categories were expanded to additionally include the 
‘neck’. The UAM Survey has multi-site ethics approval.   
 
DBS specimens were tested for antibodies to HIV (anti-HIV), hepatitis C virus (anti-HCV) and 
hepatitis B core antigen (anti-HBc). Anti-HIV was detected using an in-house GACELISA with 
similar performance to GACELISA HIV 1+2 (Abbott Murex Diagnostics Ltd, Dartford, UK). 
Reactive specimens underwent further testing according to a proven algorithm that included a 
second ELISA and Western Blot (Connell, et al., 1993).  Anti-HCV was detected using a 
previously validated commercial enzyme-immunoassay (Ortho HCV 3.0 SAVe, Ortho 
Diagnostics) (Judd, et al., 2003) and anti-HBc was detected using an in-house modification of 
the Biorad MONOLISA Anti-HBc PLUS Assay (code 72315/6) optimised and validated to 




Eligibility & analysis 
We analysed data collected in UAM Survey over the period 2011 to 2014 inclusive. Where 
respondents participated in more than one survey wave, only their first participation record was 
retained. Respondents who had not injected during the preceding 28 days, and those who 
provided no response to the question on body sites used for injection were also excluded.  
 
Bivariate associations (p<0.05) between the outcome variable, that is reporting the use of the 
neck as an injection site during the preceding 28 days, and covariates (demographics, injecting 
practices (during the preceding 28 days), sexual behaviour (during the preceding year), and 
health services’ use (during the preceding year)) were examined using Pearson’s Chi-square 
test. Where possible associations were observed (p<0.10) these were further examined via 
logistic regression to estimate crude and adjusted odds ratios (AOR) and 95% confidence 
intervals (CI) using a forward stepwise procedure to select variables for inclusion in the model 
based on the likelihood ratio test (p<0.05). All analyses were undertaken using SPSS 23. 
 
Associations between using the neck as an injection site and four health-related harms (testing 
anti-HIV, anti-HBc, anti-HCV positive, and self-reported recent symptoms of injection site 
infection during preceding year) were explored by examining the prevalence of injection into 
the neck among those with and without each of these four harms. Data were adjusted for age, 
gender and region as these factors are known to be associated with these health-related harms 






During 2011-14, a total of 5,261 unique individuals were recruited. Just over half (51%, 
n=2,679) were aged 35-years or older (mean age 35 years, median 35 years), 23% (n=1,216) 
were women and 6% (n=316) were born outside of the UK. Almost two thirds (64%, n=3,391) 
of the sample reported that the main class of drugs injected was opiates, with a further 18% 
(n=970) of respondents reported that they injected both opiates and stimulants, predominantly 
heroin and crack. A minority of respondents reported injecting only stimulants (13%, n=672) or 
other drugs (4%, n=228). Just over one quarter (28%, n=1,469) of respondents reported that 
they had been homeless during the preceding year and almost three-quarters (71%, n=3,748) 
reported that they had a history of imprisonment.  
 
Injection practice 
The most commonly reported site on the body used for injection during the preceding 28 days 
was the arm (61%, n=3,219); with 36% (n=1,872) reporting injection into their groin (femoral 
vein), 27% (n=1,422) into their hand, 21% (n=1,127) into their leg, and 11% (n=593) into their 
foot. Injection into the neck was reported by 6% (n=339) of respondents, with 4% (n=183) 
reporting that they had used another unspecified site. Overall, 67% (n=3,547) of respondents 
had used a single injection site during the preceding 28 days; while 19% (n=991) had used 
two injection sites, 8% (n=407) had used three sites and 6% (n=316) had used four or more 
injection sites. For 52 respondents (1%), the neck was the only injection site they had used in 
the preceding 28 days.  
 
    [Insert Table 1 about here] 
 
The factors associated with using the neck as an injection site in both bivariate and 
multivariable analysis are provided Table 1. In multivariable analysis, jugular vein injection was 
more common among women (AOR 1.89, 95% CI 1.42-2.52, p<0.001), those with a lifetime 
8 
 
history of imprisonment (AOR 1.51, 95% CI 1.12-2.03, p=0.041) and people who had shared 
(distributively &/or receptively) needles and syringes (AOR 1.67, 95% CI 1.25-2.24, p<0.001). 
Jugular vein injection was also associated with recent poly-drug use, with respondents 
increasingly more likely to have injected into their neck as the number of drugs injected in the 
previous 28 days increased. Similarly, the likelihood that respondents had injected into their 
neck increased as the number of injection sites increased. 
 
Health Harms 
Overall, 51% (n=2,663) of respondents had been exposed to hepatitis C (anti-HCV positive), 
15% (n=783) had ever been infected with hepatitis B (anti-HBc positive) and 1% (n=58) had 
HIV infection. Just over one quarter (28%, n=1,466) of respondents reported they had 
experienced an abscess, open sore or wound at an injection site during the preceding year.  
In both bivariate and multivariable analyses there were no associations between jugular vein 
injection and HCV, HBV or HIV infection. However, experiencing an abscess, open sore or 
wound at an injection site during the preceding year was significantly more common among 
those who used the neck as an injection site, with 46% (n=156) of respondents who reported 
jugular vein injection experiencing these symptoms, compared with 27% (n=1,310) of those 
who did not report jugular vein injection (AOR 2.31, 95% CI 1.84 to 2.89, p<0.001).  
 
Discussion 
In our study, one third of respondents reported central venous injection and one in 15 had used 
their neck as an injection site during the preceding 28 days. Given that our study only 
investigated injection practice during the previous four weeks, it is likely that a higher proportion 
had injected into their neck in the previous year or had a lifetime history of jugular vein injection. 
Our findings on the prevalence of the practice of jugular vein injection are broadly similar to 
that reported in Australia (Darke, et al., 2001), but lower than that reported in studies 
undertaken in Tijuana and Vancouver (Hoda, et al., 2008; Rafful, et al., 2015). Among the few 
studies that have investigated this practice, variation in the prevalence of injection into the 
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jugular vein is likely to be related to differences in the physical properties of the drugs being 
injected (e.g. the use of viscous ‘black tar’ heroin), and the nature of populations recruited (e.g. 
how frequently they inject). 
 
Consistent with the limited literature on jugular vein injection (Hoda, et al., 2008; Rafful, et al., 
2015), we found that women were almost twice as likely to report neck injection compared to 
men. While peripheral venous access difficulties over the longer term are relatively common 
among PWID (Ciccarone & Harris, 2015), these difficulties may be exacerbated among 
women. Several studies have demonstrated that, compared to men, women are more likely to 
experience injection-related skin and soft tissue injuries which can lead to venous sclerosis 
and loss of venous functioning (Topp, et al., 2008; El-Bassel, et al., 2010). Previous studies 
also identified an association between injecting into the jugular vein and requiring assistance 
to inject, a practice which was not asked about in our survey (Hoda, et al., 2008; Rafful, et al., 
2015).  
 
We also found associations with recent poly-drug injection, use of multiple injection sites, and 
needle and syringe sharing. One in 100 respondents had exclusively injected into their neck 
during the previous 28 days, suggesting that this is their main or usual injection site. The 
association with needle and syringe sharing is of concern, and is contrary to findings from 
Tijuana, Mexico, where neck injection was associated with use of new or sterile needles 
(Rafful, et al., 2015). Our results indicate that people who inject into the jugular vein engage in 
range of high-risk injection practices. Providers of specialist services when delivering harm 
reduction interventions should be aware that the overall levels of risk behaviours are higher 
among those who inject into their neck.  
 
The association between ever imprisonment and neck injection may also be related to those 
who inject into their jugular vein having a higher overall risk profile. Recent imprisonment was 
also weakly associated with jugular vein injection in Vancouver (Hoda, et al., 2008). Although 
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the association between jugular injection and imprisonment needs further investigation, there 
may be interplay between behaviours, such as injection in public spaces and poor injection 
practice, which might lead to greater likelihood of involvement with the criminal justice system, 
as well as to the use of the jugular vein for injection.  
 
The association between neck injection and recent symptoms of an injection site infection 
might also reflect a higher level of overall injection risk in this group. In this study we did not 
ask about the body location of the injecting site infection(s), so this association may be due to 
people who, because of an infection are unable to use their usual injection site(s), using their 
neck as an alternative injection site. This finding needs further examination. However, 
considering we also identified association between jugular injections and the use of multiple 
body sites for injecting, the association with injection site infections could be related to vascular 
access issues at other body site(s) that have resulted in people moving on to alternative higher 
risk sites, such as the jugular vein, over time (Darke, et al., 2001). 
 
Darke et al (2001) work in Australia indicated such a temporal progression in the body sites 
that PWID use for injection. They found that the initial progression was from the pit of the elbow 
(cubital fossa) to the forearm and then the upper arm. The use of the hand, legs and/or the 
neck often followed, then finally the use of the groin and/or digits. Such progressions are most 
probably related to the development of injection-related problems, such as vascular sclerosis 
and soft tissue infections and injuries, which are often experienced at frequently used injection 
sites and after injecting for long periods (Darke, et al., 2001; Harris & Rhodes, 2012; Hope, et 
al., 2016). The actual sites in such a progression and the order that they are used are probably 
affected by local injecting practices, such as what sites are already being used by other PWID, 





Considering this progression in the body sites used for injection, public health responses 
should first investigate ways to reduce the transition to, and practice of, central vein injection 
(including injection into the jugular vein) by supporting and promoting good injection site 
management and hygiene in order to minimise vascular damage, reduce problems associated 
with peripheral venous access, and promote vascular health. Further, the early treatment of 
injection site wounds and infections that do arise will help to preserve access to peripheral 
veins by reducing the likelihood of long term complications (Rhodes, et al., 2007). These 
should of course be in addition to the provision of high coverage of needle and syringe 
programmes and easy access to opiate substitution therapy (MacArthur, et al., 2014) in order 
to minimize injections using non-sterile injecting equipment that are detrimental venous health 
(Harris & Rhodes, 2012). Although these interventions, which both aim to reduce injection risk, 
are widely available in the UK, our findings show that substantial sharing and reuse of needles 
and syringes and other injecting equipment continues. Secondly, interventions should promote 
awareness among PWID of the risks that are associated with injecting into the neck. Advice 
and support should also be provided as appropriate to PWID on how to access peripheral veins 
even when they believe this is no longer possible (Zador, et al., 2008). As noted by Zador et 
al (2008), this strategy is particularly warranted in settings where injection practices are directly 
observed, such as supervised injection facilities. Finally, as smoking or snorting drugs, while 
not without risk, are safer than injecting, route transition interventions that support alternative 
routes of administration to injection should also be considered. Interventions, such as providing 
foil for heroin inhalation, have proven effective in some settings (Pizzey & Hunt, 2008; Advisory 
Council on the Misuse of Drugs, 2010). 
 
Our study has potential limitations. Firstly, the illicit and marginalised nature of injection drug 
use makes the recruitment of representative samples difficult. To maximise 
representativeness, an accepted approach for surveillance surveys involving recruitment at 
multiple sites through targeted services for PWID as a sampling frame was used (European 
Centre for Disease Prevention and Control, 2009). In the UK, the provision of targeted services 
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is extensive, and the uptake and use of these has been found to be high in community-based 
studies (Hickman, et al., 2007). Secondly, behavioural data used are based on self-reports, 
the accuracy of which may be subject to recall bias; however, the reliability of self-reported risk 
behaviours among PWID has been shown in other studies (Latkin, et al., 1993). Considering 
these issues, the findings presented here should be generalised with caution. 
 
Conclusions 
A significant minority of PWID inject into the jugular vein in the UK and serious adverse health 
consequences are associated with this practice. Public health responses should investigate 
ways to support and promote good injection site management in order to minimise vascular 
damage, reduce problems with peripheral venous access, and promote vascular heath among 
PWID. Women who inject drugs, PWID with a history of imprisonment and people who are 
experiencing early signs of injection-related skin and soft tissue injuries are priority sub-
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Table 1  Factors associated with using the neck as an injection site among people 
who inject psychoactive drugs; United Kingdom, 2011-2014 (n=5,261). 
 
  Injected into the neck?     
  Yes N p 
Adjusted Odds Ratio, 
95% CI. 
          
Gender of respondent 
Male 5.6% 225 4,045 
<0.0001 
1.00    
Female 9.4% 114 1,216 1.89 1.42 - 2.52 
          
Age, Years Mean/Median Yes 34/34;  No 35/35 0.0981‡ † 
          
Country / Region 
Midlands & Eastern England 7.0% 97 1,382 
0.0271 † 
London & Southern England 7.2% 126 1,739 
Northern England 4.9% 78 1,593 
Wales & Northern Ireland 6.9% 38 547 
          
Ever imprisoned? 
No 5.4% 81 1,513 
0.0408 
1.00    
Yes 6.9% 258 3,748 1.51 1.12 - 2.03 
          
Homeless during 
preceding year 
No 6.1% 230 3,792 
0.0726 † 
Yes 7.4% 109 1,469 
          
Shared needle(s) or 
syringe(s) *  
No 5.4% 239 4,413 
<0.0001 
1.00    
Yes 12% 100 848 1.67 1.25 - 2.24 
          
Shared a mixing 
container(s)* 
No 5.3% 195 3,704 
<0.0001 † 
Yes 9.2% 144 1,557 
          
Shared a filter(s)* 
No 5.3% 207 3,896 
<0.0001 † 
Yes 9.7% 132 1,365 
          
Injected with needle/ 
syringe after cleaning* 
No 5.7% 212 3,725 
0.0005 † 
Yes 8.3% 127 1,536 
          
Number of injection 
sites used* 
One 1.5% 52 3,547 
<0.0001 
1.00    
Two 5.8% 57 991 3.92 2.67 - 5.77 
Three 21% 85 407 16.4 11.4 - 23.8 
Four or more 46% 145 316 48.6 33.9 - 69.6 
          
Main drug type 
injected* 
Opiates only 5.5% 188 3,391 
<0.0001 † 
Stimulants only 4.6% 31 672 
An opiate & stimulant 11% 107 970 
Other drugs or combinations 5.7% 13 228 
          
Number of drugs 
injected* 
One 3.7% 96 2614 
<0.0001 
1.00    
Two 7.7% 150 1954 2.11 1.57 - 2.84 
Three 11% 58 511 2.10 1.42 - 3.12 
Four or more 19% 35 182 3.02 1.81 - 5.05 
          
Number of times 
injected*  
 <14 3.5% 55 1,550 
<0.0001 † 
 14-27 3.8% 26 682 
 28-56 5.5% 61 1,113 
 57+ 11% 147 1,357 
Not reported 8.9% 50 559 
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Ever exchanged sex 
for money, drugs or 
goods? 
Never/not reported 6.0% 275 4,621 
<0.0001 † Yes, not in preceding year 6.3% 20 320 
Yes, in preceding year 14% 44 320 
          
Needle & syringe 
programme use and 
coverage (needles per 
injection*) 
Not used 4.7% 15 321 
0.0143 † 
Used: coverage 100% or less 7.0% 149 2,121 
Used: coverage over 100% 5.3% 102 1,911 
Use &/or coverage not known 8.0% 73 908 
          
There was no association in the bivariate analyses with: whether UK born; reporting anal &/or vaginal sex last year;  being prescribed 
treatment for drug use; ever having voluntary confidential test for HIV;  ever having voluntary confidential test  for hepatitis C; or uptake 
of the hepatitis B vaccine. 
Years since first injection was not considered in the analysis as age at first injection was sometimes missing, and where years since 
first injection could be calculated it was found to be correlated with age (r=0.661, p<0.001). 
 
* During preceding 28 days.         
‡ Mann Whitney U          
† Not in final model          
95% CI = 95% confidence interval         
 
 
